Dr. Bernice Lo is a Principal Investigator in the Precision Medicine program at Sidra Medicine and an Adjunct Assistant Professor at Hamid bin Khalifa University (Doha, Qatar). She has contributed to the discovery, diagnosis, and molecular understanding of inherited autoimmune disorders. Bernice performed her post-doctoral training under the leadership of Dr. Michael Lenardo in the Laboratory of Immunology at the National Institutes of Health in the US. She is trained in cell and molecular biology and genomic approaches for genetic diagnosis. During her fellowship, she helped discover and understand the etiology of two new diseases of immune dysregulation. She received her Ph.D. in Cell Biology at Duke University under the mentorship of Dr. Jo Rae Wright, where she began her appreciation for the immune system and the critical role of immune tolerance and regulation.
The research focus of Dr. Lo’s laboratory is on understanding the molecular mechanisms of immune regulation and tolerance. Her approach includes identifying the genetic basis of disease in patients with immune dysregulation and autoimmunity with the ultimate goal of elucidating the molecular pathways involved and, therefore, revealing new therapeutic targets for disease treatment or novel drugs for immunomodulation.Dr. Lo’s lab specializes in using cellular and biochemical techniques to uncover the role of newly discovered gene mutations in causing disease and in understanding the function of these genes in immune regulation. Her research interests also include identifying modifier genes and elucidating their functional role in immunologic disorders with incomplete penetrance. She is also interested in developing methods for disease diagnosis or evaluating treatment efficacy by assessing immune biomarkers.
Ussama Abdel-Motal, PhDStaff ScientistEmail: uabdelmotal (@) sidra.orgRafah Mackeh, PhDStaff ScientistEmail: rmackeh (@) sidra.orgNourhen Agrebi, PhDPostdoctoral FellowEmail: nagrebiepmansour (@) sidra.orgSatanay Hubrack, MScResearch SpecialistEmail: shubrack (@) sidra.orgAhmad Al-Shaibi, MScResearch SpecialistEmail: aalshaibi (@) sidra.orgAmera Sadoun, MScResearch SpecialistEmail: asadoun (@) sidra.orgMohamed Alsabbagh, MScResearch SpecialistEmail: malsabbagh-c (@) sidra.orgAmnah Al-Marri, BScResearch SpecialistEmail: aalmarri2 (@) sidra.org
SELECTED PUBLICATIONS(†equal contribution, *corresponding):
- Cagdas D, Halaçlı SO, Tan Ç, Lo B, Çetinkaya PG, Esenboğa S, Karaatmaca B, Matthews H, Balcı-Hayta B, Arıkoğlu T, Ezgü F, Aladağ E, Saltık-Temizel İN, Demir H, Kuşkonmaz B, Okur V, Gümrük F, Göker H, Çetinkaya D, Boztuğ K, Lenardo M, Sanal Ö, Tezcan İ. “A Spectrum of Clinical Findings from ALPS to CVID: Several Novel LRBA Defects.” J Clin Immunol (2019) doi: 10.1007/s10875-019-00677-6.
- Kiykim A, Ogulur I, Dursun E, Charbonnier LM, Nain E, Cekic S, Dogruel D, Karaca NE, Cogurlu MT, Bilir OA, Cansever M, Kapakli H, Baser D, Kasap N, Kutlug S, Altintas DU, Al-Shaibi A, Agrebi N, Kara M, Guven A, Somer A, Aydogmus C, Ayaz NA, Metin A, Aydogan M, Uncuoglu A, Patiroglu T, Yildiran A, Guner SN, Keles S, Reisli I, Aksu G, Kutukculer N, Kilic SS, Yilmaz M, Karakoc-Aydiner E, Lo B, Ozen A, Chatila TA, Baris S. “Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency.” J Allergy Clin Immunol Pract. (2019) .
- Abdel-Motal UM, Al-Shaibi A, Elawad M, Lo B. “Zero tolerance! A perspective on monogenic disorders with defective regulatory T cells and IBD-like disease.” Immunol Rev. (2019) 287 (1):236-240.
- Lo B, Abdel-Motal UM. “Lessons from CTLA-4 deficiency and checkpoint inhibition.” Curr Opin Immunol (2017) 49:14-19.
- Lo B, Fritz JM, Su HC, Uzel G, Jordan MB, Lenardo MJ. “CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency.” Blood(2016) 128(8): 1037-42.
- Lenardo M,Lo B, Lucas CL. “Genomics of Immune Diseases and New Therapies.” Annu Rev Immunol (2016) 20;34:121-49.
- LoB*, ZhangK*, Lu W, Zheng L, Zhang Q, Kanellopoulou C, Zhang Y, Liu Z, Fritz JM, MarshR, HusamiA, KissellD, NortmanS, ChaturvediV, HainesH, YoungLR, MoJ, FilipovichAH, Bleesing JJ, Mustillo P, Stephens M, Rueda CM, Chougnet CA, Hoebe K, McElweeJ, HughesJD, Karakoc-Aydiner E, MatthewsHF, PriceS, Su HC, RaoVK, LenardoMJ, Jordan MB. “Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.” Science.(2015) 349(6246):436-40.
- Kuehn HS*, Ouyang W*, Lo B*, Deenick EK, Niemela JE, Avery DT, Schickel JN, Tran DQ, Stoddard J, Zhang Y, Frucht DM, Dumitriu B, Scheinberg P, Folio LR, Frein CA, Price S, Koh C, Heller T, Seroogy CM, Huttenlocher A, Rao VK, Su HC, Kleiner D, Notarangelo LD, Rampertaap Y, Olivier KN, McElwee J, Hughes J, Pittaluga S, Oliveira JB, Meffre E, Fleisher TA, Holland SM,Lenardo MJ, Tangye SG, Uzel G. “Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.” Science(2014) 345(6204):1623-7.
- Price S, Shaw PA, Seitz A, Joshi G, Davis J, Niemela JE, Perkins K, Hornung RL, Folio L, Rosenberg PS, Puck JM, Hsu AP, Lo B, Pittaluga S, Jaffe ES, Fleisher TA, Rao VK, Lenardo MJ. “Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations.” Blood(2014) 123 (13):1989-99.
- Lo B, Hansen S, Evans K, Heath JK, and Wright JR. “Alveolar epithelial type II cells induce T cell tolerance to specific antigen.” J Immunol(2008) 180: 881-888.